1 / 1
Custom Setmelanotide CAS: 920014-72-8 Manufacturer, Service
Product Description
Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist used to treat a rare genetic obesity disorder caused by a specific gene defect. It helps restore energy balance and weight control in patients by activating the MC4R pathway in the hypothalamus (which plays a central role in regulating hunger, energy expenditure, and weight).
Mechanism of Action
Selectively activates MC4R, mimicking α-MSH to reduce hunger and increase satiety.
Administration Method
Subcutaneous injection once daily.
Primary Targets
POMC/PCSK1 deficiency, LEPR deficiency, and BBSome gene-related obesity.
Therapeutic Areas
Monogenic Obesity
-
POMC/PCSK1 deficiency:
Patients have insufficient activation of the MC4R pathway due to mutations in POMC or PCSK1 genes, manifesting as early severe obesity and adrenal insufficiency.
-
LEPR deficiency:
A defect in the leptin receptor leads to failure of leptin signaling, causing intense hunger and uncontrolled weight gain.
Syndrome-Related
-
Bardet-Biedl syndrome (BBS):
A multi-system ciliary disorder often accompanied by severe obesity, retinopathy, and polydactyly.
-
Alström syndrome (Phase Trials):
A multisystemic disease similar to BBS, accompanied by early obesity and metabolic abnormalities.
MC4R Pathway Variants
-
Other Gene Variants:
Further research is underway exploring other gene variants involving the MC4R pathway (such as SH2B1, NCOA1, etc.).
Outlook & Development
1. Market & Clinical Standing
- Approved Indications: FDA and EMA approved for obese patients aged 6 years and older with POMC/PCSK1/LEPR deficiency or BBS.
- Efficacy Data: Pivotal clinical trials showed significant weight loss (≥10%) and substantial hunger score improvements for most patients.
- Commercialization: Priced as a high-value rare disease treatment; accessibility is expanding through health insurance negotiations.
2. Expansion of R&D Pipeline
- Generalized MC4R Pathway Obesity: The TEMPO registry study explores therapeutic effects on patients with other MC4R pathway gene variants to expand indications.
- Combination Therapies: Combining with metabolic drugs like GLP-1 receptor agonists may offer effectiveness for broader obese populations.
3. Challenges & Opportunities
- Small Patient Population: Market size is limited by rare disease indications; requires long-term real-world data verification.
- Administration Method: Daily injection impacts compliance; oral formulations remain in development.
- Competitive Landscape: Must consolidate its irreplaceable precision medicine position against general obesity GLP-1 drugs.
- Precision Medicine Paradigm: Serves as a pioneer for gene-guided therapy in genetic obesity.
- Pediatric Market: Addressing growing demand for early intervention in childhood rare genetic obesity.
4. Market Prospects
- Short-Term: Solidify its standing as the standard treatment in rare hereditary obesity as genetic testing expands.
- Long-Term: Expanding into broader MC4R-related subtypes or novel combination therapies offers significant market growth. Development of oral or long-acting formulations remains a major key objective.
Conclusion
In summary, Setmelanotide is a breakthrough therapy in the field of rare genetic obesity, filling a clinical gap by precisely targeting the MC4R pathway. Its future value will depend on the expansion of its indications, the development of combination therapies, and its deeper positioning in precision obesity medicine.
Frequently Asked Questions
What is Setmelanotide and how does it work?
Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist designed to treat rare genetic obesity. It functions by selectively activating the MC4R pathway in the hypothalamus, restoring energy balance, increasing satiety, and reducing hunger.
How is Setmelanotide administered to patients?
It is administered via a subcutaneous injection once daily.
Which indications are approved for Setmelanotide?
Setmelanotide is FDA and EMA approved for patients aged 6 years and older with POMC/PCSK1 deficiency, LEPR deficiency, or Bardet-Biedl syndrome (BBS).
What are the main therapeutic focus areas for Setmelanotide?
Therapeutic areas include monogenic obesity (POMC/PCSK1 and LEPR deficiency), syndrome-related obesity (Bardet-Biedl syndrome and Alström syndrome), and other specific MC4R pathway gene variants.
What are the future opportunities and expansion plans for Setmelanotide?
Future growth relies on expanding indications to broader MC4R pathway variants, exploring combination therapies with GLP-1 agonists, developing potential oral/long-acting formulations, and increasing penetration through widespread genetic testing.
